ToxGenSolution

Profiling your product through the complex multidimensional relationships between exposure, biological response, and human health outcome

For customized adverse outcome pathway-based animal-free testing and assessment strategies

The latest news from

ToxGenSolution

BREAKING NEWS

  • TOXGENSOLUTIONS REPRESENTED THE INTERREG. PROJECT ”MEMORIES” DURING THE 29th ALZHEIMER’S EUROPE CONGRESS IN THE HAGUE.

    ToxGenSolutions presented a poster showing the approach adopted by the Interreg. project to develop a test for diagnosis of Alzheimer’s disease before it strikes (29th AEC_poster_PO.20.11). The congress was characterized by a high representation of technologies and technological developments that focusses on monitoring the patients. Presentations on scientific progress were limited, and focussing on the clinical phase of disease: ”Looking at Alzheimer’s through the peephole of dementia” as one of the speakers stated. Beside our poster, there was little, if at all, focus on the impact of environmental factors on induction and development of Alzheimer’s.  

  • INTERREG. PROJECT ”HERINNERINGEN”: SYMPOSIUM ‘STOP ALZHEIMER’ on Monday December 16, 2019

    The INTERREG Vlaanderen-Nederland project ”Herinneringen” (”Memories”) organises its 2019 Symposium STOP ALZHEIMER on Monday December 16 in the wonderful ‘Promotiezaal’ of the Katholieke Universiteit Leuven (Naamsestraat 22, 3000 Leuven).
    The programme offers science (in English) and more down-to-earth information (in Dutch) targeting patients, patient organizations and healthcare workers. There will be space for questions, discussion and networking in a relaxed atmosphere.

  • NEWSLETTER: INTERREG. PROJECT ”HERINNERINGEN” (”MEMORIES”), issue 3

    1. Optimization of in vitro exposure regimes to assure risk factor induced adverse effects in the absence of cytotoxicity.
    2. Hitting the road.

    Newsletter_072019

  • INVITATION TO THE 2019 SYMPOSIUM OF THE INTERREG. PROJECT ”HERINNERINGEN” (”MEMORIES”)

    The #interreg project #Herinneringen applies #animalfree approaches to understand the #adverseoutcomepathways (#AOP) driving sporadic #alzheimersdisease.

  • NEW TOOL FOR PREVENTIVE MEDICINE: DETECTING ALZHEIMER’S BEFORE IT BECOMES A DISEASE

    TGS is valorising a human relevant test method, based on a specific biomarker profile representing Alzheimer’s related neuronal processes before cell death occurs.

  • THE INTERREG. PROJECT HERINNERINGEN (‘MEMORIES’) 2018 SYMPOSIUM ON EARLY BIOMARKERS FOR SPORADIC ALZHEIMERS

    THE INTERREG. PROJECT HERINNERINGEN (‘MEMORIES’) 2018 SYMPOSIUM ON EARLY BIOMARKERS FOR SPORADIC ALZHEIMERS

    27.11.2018 BY TOXGENSOLUTIONS BV
    Many thanks to the participants, and especially the speakers: Catherine Verfaillie (KULeuven (host)), Francesca Pistollato (EURLECVAM (invited speaker)), Annemie Ribbens (icometrix), Sebastiaan Engelborghs (UAntwerpen), Gerard Griffioen (reMYND), Jacco Briede and Rob Schlooz (UMaastricht) and Erwin L Roggen (ToxGenSolutions).

    The presentations will soon be available on toxgensolutions.eu.

  • TOXGENSOLUTIONS BV INVITES APPLICATIONS FOR A POSITION AS EXPERIENCED RESEARCHER, STARTING JANUARY 1, 2019.

    TOXGENSOLUTIONS BV INVITES APPLICATIONS FOR A POSITION AS EXPERIENCED RESEARCHER, STARTING JANUARY 1, 2019.

    16.11.2018 BY TOXGENSOLUTIONS BV

    POSITION FOR AN EXPERIENCED RESEARCHER

    ToxGenSolutions BV invites applications for a position as experienced researcher, starting January 1, 2019.

    ToxGenSolutions BV invites applications for a position as experienced researcher, starting January 1, 2019.

    You see you self as a researcher at a spin-off company based at the University of Maastricht with an ambition to expand. The research field is Neurodegeneration of the human brain, with focus on Alzheimer’s Disease (AD).

    The successful candidate will participate in an AD project supported by EU Interreg. Vlaanderen – Nederland, het Nederlands Ministerie van Economische Zaken, de Provincie Nederlands Limburg, Vlaams Agentschao Innoveren en Ondernemen (VLAIO) and the Provinces of Antwerpen and Vlaams Brabant.

    RESPONSIBILITIES AND TASKS:

    • Experimental planning of the project, problem solving and assuring compliance with the timelines of the project.
    • Laboratory work within the field of microRNA detection.
    • Performance of differential (epi-)genomics and pathway analyses.
    • Handling and reporting of experimental data.
    • Preparing microRNA profiles with diagnostic value for the market.

    QUALIFICATIONS:
    Applicants should have a PhD degree in (epi)genomics or equivalent with several years of experience.

    THE PROFILE OF THE IDEAL CANDIDATE:

    • You have experience with and enjoy laboratory work.
    • You have hands-on experience with state-of-the-art (epi-)genomics technologies.
    • Experience in bioinformatics will be considered an advantage.
    • You communicate fluently in English.
    • You can work with deadlines and pressure.
    • You are flexible, enthusiastic and responsible, with team spirit and excellent collaboration skills.

    WE OFFER:
    ToxGenSolutions BV offers a competitive scientific environment with the ambition to build a self-sustainable company applying front-edge non-animal toxicogenomics approaches on human health problems to provide the customer with genetic biomarker fingerprints for application in novel more accurate methods for diagnosis, novel tools for follow-up of disease progression or response to treatment in humans, and novel drug development.

    SALARY AND TERMS OF EMPLOYMENT:
    The appointment will be based on the current wage scales that are applied by the University of Maastricht. The position is for two years.

    FURTHER INFORMATION:
    For additional information about the position, please contact Erwin L Roggen (erwin.roggen@toxgensolutions.eu).

    You can read more about ToxGenSolutions BV on www.toxgensolutions.eu.

    APPLICATION PROCEDURE:
    Please submit your application no later than December 10, 2018 (Local time). Applications and enclosures received after the deadline will not be considered.

    Applications must be submitted as one PDF file containing all your materials in English. The file must include:

    • Application (cover letter)
    • CV
    • Diploma (MSc)

    All interested candidates irrespective of age, gender, disability, race, religion or ethnic background are encouraged to apply.


  • YOU ARE HEREBY CORDIALLY INVITED TO THE FIRST ANNUAL MEETING ON NOVEMBER 23TH 2018 IN BUILDING ON1 AT THE KATHOLIEKE UNIVERSITY LEUVEN (HERESTRAAT 49, LEUVEN).

    YOU ARE HEREBY CORDIALLY INVITED TO THE FIRST ANNUAL MEETING ON NOVEMBER 23TH 2018 IN BUILDING ON1 AT THE KATHOLIEKE UNIVERSITY LEUVEN (HERESTRAAT 49, LEUVEN).

    23.10.2018 BY TOXGENSOLUTIONS BV

    The project ‘Herinneringen’ (‘Memories’) is about to finish the first year of its search for a cost-effective and minimally invasive method allowing for accurate diagnosis of (sporadic) Alzheimer’s disease (AD) before significant damage to the brain has occurred.

    You are hereby cordially invited to the first annual meeting on November 23th 2018 in building ON1 at the katholieke University Leuven (Herestraat 49, Leuven). Participation is free but registrations via the project web site (Menu, Contact) is required for practical reasons.

    The program can be downloaded from the same web site. Francesca Pistollato from the European Reference Laboratory – European Center for validation of Alternative methods to Animal Testing (EURL-ECVAM) will address the current challenges met by traditional AD research, and the need for the paradigm shift that forms the basis of the project ‘‘Herinneringen’ (‘Memories’).

    The project partners will present an overview of the different activities that are planned to meet the final goal, and progress will be reported where relevant. Special attention will be given to (i) the selection of the external risk factors for sporadic AD; (ii) the cell-based methods for identification of molecular and cellular processes that may be involved in the onset and early development of AD-related processes; (iii) the strategies to scientifically validated the human relevance of the identified potential biomarkers. See you November 23th.

Higher relevance & revenues

HOW DOES IT WORK?

A VIRTUAL GENERIC GENOMICS-BASED PLATFORM THAT PROVIDES ANSWERS TO YOUR QUESTIONS ABOUT SAFETY AND EFFICACY OF YOUR PRODUCTS.

NEXT-GENERATION TOOLS

  • A systems-based technology platform for profiling the positive as well as negative impact of your product on biological response and human health at realistic concentrations and under relevant exposure regimes.
  • Our toolbox contains a breadth of technologies, systems, and pathways of toxicity and common nodes of toxicity developed by the Netherlands ToxicoGenomics Center (2008-2013).
  • The ToxGenSolutions toolbox is also useful for the identification of new opportunities for product development
  • The ToxGenSolutions toolbox is flexible, faster than traditional methods, more economical and more relevant for human safety and health.

FRONT-EDGE TECHNOLOGIES

  • ToxGenSolutions products are proprietary mechanism-based gene signatures for identification and classification of toxicants during screening, product development and safety assessment.
  • ToxGenSolutions provides a cutting-edge patchwork of test methods required for modern testing and assessment of compounds and products.
  • ToxGenSolutions builds on a virtual generic platform of leading test and technology developers providing novel technologies addressing key events in outcome pathways.

FOCUS ON YOUR NEEDS

  • ToxGenSolutions develops testing and assessment strategies for, and with, you to assure optimal coverage of your needs.
  • ToxGenSolutions develops strategies considering the nature of the test substance, the intended application, likely exposure routes, product development status and legislation.

An applied systems toxicology approach

FOR A SAFER FUTURE

THE WORKING HYPOTHESIS IS THAT THE COMBINATION OF EXPERTISE AND TECHNOLOGY FROM DIFFERENT DISCIPLINES WILL PROVIDE THE UNDERSTANDING OF HOW CHEMICALS INTERACT WITH BIOLOGICAL SYSTEMS THAT IS REQUIRED TO IMPROVE HUMAN SAFETY AND HEALTH.

ToxGensolutions
For customized adverse outcome pathway-based animal-free testing and assessment strategies

STILL ON THE TABLE

IMPROVING #ANIMALFREE TESTING AND ASSESSMENT BY COMBINING PHYSICO-CHEMICAL/STRUCTURAL ANALYSIS AND BIOLOGICAL PATHWAY ANALYSIS OF EXPOSED HUMAN CELLS AND TISSUEL.

(Q)SAR modeling is currently used to identify chemicals that are most likely to become a product,by having desired physico-chemical/structural characteristics (e.g. new leads for drug development), and by not exhibiting characteristics known to exert adverse effects in humans (e.g. hazard identification and safety testing).

It is currently not well established how well current (Q)SAR models discriminate chemicals with similar physico-chemical/structural characteristics but different in vivo outcome. This is a problem e.g. when in vivo animal models incorrectly indicate unsatisfactory efficacy or toxicity.

ToxGenSolutions BV envisages a novel quantitative systems biology approach for toxicity assessment linking physico-chemical characteristics of test compounds ((Q)SAR) with biological impact on cells/tissues, providing more accurate human health and safety where in vivo animal models fail.

A NOVEL THERAPY FOR SLOWING DOWN THE PROGRESSION OF NEURODEGENERATIVE DISEASES THROUGH A BETTER UNDERSTANDING OF THE IMPACT OF ENVIRONMENTAL CHEMICALS ON NEURODEGENERATION INDUCTION.

The incidence of neurodegenerative diseases (e.g. Alzheimer’s, Parkinson, multiple and amyotrophic lateral sclerose) is globally on the rise, and the increasing number of patients is challenging the existing medical care ressources.

While these diseases are driven by genetics, there is also an important environmental input. Despite decennia of intensive research early diagnose and effective therapy of these diseases is not yet possible. There are two important hurtles:

1. The underlying mechanisms of induction of neurodegeneration in humans are still not sufficiently understood;

2. The blood-brain barrier allows only chemicals with specific physicochemical charactereistics to enter the brain. ToxGenSolutions BV envisages a project addressing the mechanistic aspects (Hurtle 1). -Omics approaches based on human stemcells and tissues are anticipated (i) to provide better and more relevant knowldege about the mechanisms affected by environmental factors and driving the induction of neurodegenerative diseases in humans, and (ii) to allow for the identification of human-relevant early biomarkers. Thus, the acquired knowledge offers new opportunities for the development of novel more accurate methods for early diagnosis of disease induction. In addition, alternative targets for novel anti-neurodegenerative drugs are anticipated to emerge from this project.

INFORMATION

Do you have any questions to our services then you are welcome to contact us today. Call us or send an email and then we will reply as soon as possible.

CONTACT ADDRESS

ToxGenSolutions B.V.
Oxfordlaan 70
6229 EV Maastricht, The Netherlands

CONTACT US